Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

PURPOSE: The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pan...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Chemother Pharmacol
Prif Awduron: Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., Wilmink, J. W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2015
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4441736/
https://ncbi.nlm.nih.gov/pubmed/25822310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2730-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg